Perioperative Immunotherapy Significantly Improves NSCLC Outcomes
University of Texas MD Anderson Cancer Center
Results showed a 32 percent lower chance of cancer recurrence, progression, or death with immunotherapy plus chemotherapy versus chemotherapy alone